<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> is an important and potentially lethal complication of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>The blood count has been reviewed in <z:hpo ids='HP_0000001'>all</z:hpo> patients treated with <z:chebi fb="2" ids="2948">azathioprine</z:chebi> for <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> over 27 years in one hospital </plain></SENT>
<SENT sid="2" pm="."><plain>Altogether 739 patients (422 with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, 284 with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, and 33 with indeterminate <z:hpo ids='HP_0002583'>colitis</z:hpo>) were treated with 2 mg/kg/day <z:chebi fb="2" ids="2948">azathioprine</z:chebi> for a median of 12.5 months (range 0.5-132) between 1964 and 1991 </plain></SENT>
<SENT sid="3" pm="."><plain>Full blood counts were performed monthly for the duration of treatment </plain></SENT>
<SENT sid="4" pm="."><plain>In 37 patients (5%) who developed <z:e sem="disease" ids="C0948168" disease_type="Disease or Syndrome" abbrv="">bone marrow toxicity</z:e>, the drug was withdrawn or the dose reduced </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty two of these patients were asymptomatic and five developed symptoms </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">Leucopenia</z:e> (white blood count less than 3.0 x 10g/l) occurred in 28 (3.8%) patients, in nine of whom it was severe (white blood count &lt; 2.0 x 10(9)/l) </plain></SENT>
<SENT sid="7" pm="."><plain>Of these nine patients, three were pancytopenic: two died from <z:hpo ids='HP_0100806'>sepsis</z:hpo> and the other had <z:hpo ids='HP_0002090'>pneumonia</z:hpo> but recovered </plain></SENT>
<SENT sid="8" pm="."><plain>A further two patients with severe <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> developed a mild upper <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> only </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> (platelet count &lt; 100,000 x 10(6)/l) in 15 patients was associated with <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> in six and developed in isolation in a further nine (total 2%) </plain></SENT>
<SENT sid="10" pm="."><plain>Isolated <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> was never clinically severe </plain></SENT>
<SENT sid="11" pm="."><plain>Myelotoxicity from <z:chebi fb="2" ids="2948">azathioprine</z:chebi> developed at any time during drug treatment (range 2 weeks-11 years after starting the drug) and occurred either suddenly or over several months </plain></SENT>
<SENT sid="12" pm="."><plain>Bone marrow suppression as a result of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> treatment is uncommon when a moderate dose is used, but is potentially severe </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">Leucopenia</z:e> is the commonest and most important haematological complication </plain></SENT>
<SENT sid="14" pm="."><plain>Regular monitoring of the full blood count is recommended during treatment </plain></SENT>
</text></document>